Study of long-term effects of pelvic radiotherapy on the function of bone marrow in recurrent cervical cancer patients

被引:0
|
作者
Deng, Boer [1 ]
Kong, Weimin [1 ]
Han, Chao [1 ]
Zhou, Chunxiao [2 ,3 ]
Li, Jing [1 ]
Song, Dan [1 ]
Lin, Yuxuan [1 ]
机构
[1] Capital Med Univ, Beijing Obstet & Gynecol Hosp, Beijing Maternal & Child Hlth Care Hosp, Dept Gynecol, Beijing 100006, Peoples R China
[2] Univ North Carolina Chapel Hill, Div Gynecol Oncol, Chapel Hill, NC USA
[3] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
来源
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES | 2024年 / 21卷 / 10期
关键词
Cervical cancer; radiotherapy; relapse; bone marrow suppression; HEMATOLOGIC TOXICITY; PRACTICE GUIDELINE; RADIATION-THERAPY; AMERICAN SOCIETY; ADVERSE EVENTS; CHEMORADIATION; CHEMOTHERAPY; CHALLENGES; COLLEGE;
D O I
10.7150/ijms.95900
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To study the effects of prior pelvic radiotherapy on bone marrow suppression in recurrent cervical cancer patients during chemotherapy. Methods and materials: The cases of 129 patients with recurrent cervical cancer were reviewed, of which 77 patients had pelvic radiotherapy history and another 52 patients with no pelvic radiotherapy history were used as control group. All patients received a chemotherapy regimen of paclitaxel combined with carboplatin (TC) per 21 days for 5-6 times. Hematologic toxicity, including count of red blood cell, white blood cell and neutrophil cell and platelet, was defined by using Common Terminology Criteria for Adverse Events (version 4.0). The relationship between age, body mass index, disease free survival, pathological types, FIGO stages, radiotherapy methods and the degree of bone marrow suppression during chemotherapy was statistically analyzed, respectively, for all recurrent cervical cancer patients. Results: Among 77 patients with previous radiotherapy history, 73 recurrent patients (94.8%) had bone marrow suppression followed by chemotherapy. Recurrent cervical cancer patients without prior radiotherapy (n=52) showed a lower risk of bone marrow suppression followed by chemotherapy (n=39, 75.0%, P < 0.05). The probability of severe bone marrow suppression (grade III-IV) after chemotherapy in recurrent cervical patients with or without history of radiotherapy was 41.6% and 13.5%, respectively (P < 0.05). In univariate analysis, radiotherapy methods were associated with the incidence of grade III-IV bone marrow suppression in recurrent cervical cancer patients (P=0.005). In multivariate analysis, radiotherapy methods and extended-field radiotherapy were the risk factor of grade III-IV bone marrow suppression (chi 2=16.975, chi 2 =16.975, P=0.001). No significant differences in the counts of white blood cell, hemoglobin and platelet were observed before chemotherapy at relapse between patients with and without prior radiotherapy. Reduction of white blood cell counts, absolute value of neutrophil cell and platelet counts composited majority type of grade III and IV bone marrow suppression. Conclusions: The prior pelvic radiotherapy significantly increased the incidence of bone marrow suppression during chemotherapy in recurrent cervical cancer patients. When treating recurrent cervical cancer patients with chemotherapy who had prior radiotherapy, especially for those experienced external beam radiation therapy, essential attention and timely intervention are recommended to ensure completion of chemotherapy and clinical efficacy.
引用
收藏
页码:2000 / 2010
页数:11
相关论文
共 50 条
  • [21] Long-term survival and risk of second cancers after radiotherapy for cervical cancer
    Ohno, Tatsuya
    Kato, Shingo
    Sato, Shinichiro
    Fukuhisa, Kenjiro
    Nakano, Takashi
    Tsuji, Hirohiko
    Arai, Tatsuo
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : 740 - 745
  • [22] Definitive pelvic radiotherapy for patients with newly diagnosed stage IVB cervical cancer: a systematic review
    Viveros-Carreno, David
    Vieira-Serna, Santiago
    Grillo-Ardila, Carlos Fernando
    Rodriguez, Juliana
    Mora-Soto, Nathalia
    Jhingran, Anuja
    Ramirez, Pedro T.
    Pareja, Rene
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (07) : 1057 - 1062
  • [23] Optimal dose limitation strategy for bone marrow sparing in intensity-modulated radiotherapy of cervical cancer
    Bao, Zhirong
    Wang, Dajiang
    Chen, Shupeng
    Chen, Min
    Jiang, Dazhen
    Yang, Chunxu
    Liu, Hui
    Dai, Jing
    Xie, Conghua
    RADIATION ONCOLOGY, 2019, 14 (01):
  • [24] General health status of long-term cervical cancer survivors after radiotherapy
    Uk, Lee Sung
    Ae, Kim Young
    Young-Ho, Yoon
    Yeon-Joo, Kim
    Cheol, Lim Myong
    Sang-Yoon, Park
    Sang-Soo, Seo
    Eun, Park Ji
    Joo-Young, Kim
    STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 (07) : 543 - 551
  • [25] Long-term outcomes of concomitant cisplatin plus radiotherapy versus radiotherapy alone in patients with stage IIIB squamous cervical cancer: A randomized controlled trial
    Dias Fachini, Ana Maria
    Zuliani, Antonio Carlos
    Sarian, Luis Otavio
    Teixeira, Julio Cesar
    Barros Esteves, Sergio Carlos
    Machado, Helymar da Costa
    Zeferino, Luiz Carlos
    GYNECOLOGIC ONCOLOGY, 2021, 160 (02) : 379 - 383
  • [26] Long-term results of radiotherapy in anaplastic thyroid cancer
    Dumke, Anne-Katrin
    Pelz, Tanja
    Vordermark, Dirk
    RADIATION ONCOLOGY, 2014, 9
  • [27] Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial
    Huang, Jin
    Gu, Fei
    Ji, Tianlong
    Zhao, Jing
    Li, Guang
    RADIATION ONCOLOGY, 2020, 15 (01)
  • [28] Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients
    van Meir, H.
    Nout, R. A.
    Welters, M. J. P.
    Loof, N. M.
    de Kam, M. L.
    van Ham, J. J.
    Samuels, S.
    Kenter, G. G.
    Cohen, A. F.
    Melief, C. J. M.
    Burggraaf, J.
    van Poelgeest, M. I. E.
    van der Burg, S. H.
    ONCOIMMUNOLOGY, 2017, 6 (02):
  • [29] LONG-TERM RESULTS OF A PROSPECTIVE, PHASE II STUDY OF LONG-TERM ANDROGEN ABLATION, PELVIC RADIOTHERAPY, BRACHYTHERAPY BOOST, AND ADJUVANT DOCETAXEL IN PATIENTS WITH HIGH-RISK PROSTATE CANCER
    DiBiase, Steven J.
    Hussain, Arif
    Kataria, Ritesh
    Amin, Pradip
    Bassi, Sunakshi
    Dawson, Nancy
    Kwok, Young
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (03): : 732 - 736
  • [30] Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer
    Maduro, JH
    Pras, E
    Willemse, PHB
    de Vries, EGE
    CANCER TREATMENT REVIEWS, 2003, 29 (06) : 471 - 488